Drug Trial Radar · NCT02563106
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
Last checked: Nov 19, 2026Latest source record: Nov 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
413
Actual
Start
Oct 2015
Primary completion
Nov 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Theriva Biologics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in Hospitalized Patients receiving IV ceftriaxone with a Diagnosis of a Lower Respiratory Tract Infection (LRTI).
Conditions
- Clostridium Difficile
- Clostridium Infections
Interventions
SYN-004Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up.Time frame: Day 1 to the 4 week Follow-up Visit.
Locations
43 sites in 7 countries. Site status is shown where the registry gives one.
Synthetic Biologics Investigational Site
Little Rock, Arkansas
Synthetic Biologics Investigational Site
Torrance, California
Synthetic Biologics Investigational Site
DeLand, Florida
Synthetic Biologics Investigational Site
Będzin, Louisiana
Synthetic Biologics Investigational Site
Debrecen, Louisiana
Synthetic Biologics Investigational SIte
Natchitoches, Louisiana
Synthetic Biologics Investigational Site
Gabrovo, Bulgaria
Synthetic Biologics Investigational Site
Kyustendil, Bulgaria
Synthetic Biologics Investigational Site
Lovech, Bulgaria
Synthetic Biologics Investigational Site
Multiple Locations, Bulgaria
Synthetic Biologics Investigational Site
Rousse, Bulgaria
Synthetic Biologics Investigational Site
Sevlievo, Bulgaria
Synthetic Biologics Investigational Site
Sofia, Bulgaria
Synthetic Biologics Investigational Site
Targovishte, Bulgaria
Synthetic Biologics Investigational Site
Sherbrooke, Canada
Synthetic Biologics Investigational Site
Toronto, Canada
Synthetic Biologics Investigational Site
Balassagyarmat, Hungary
Synthetic Biologics Investigational Site
Budapest, Hungary
Synthetic Biologics Investigational Site
Veszprém, Hungary
Synthetic Biologics Investigational Site
Bialystok, Poland
Synthetic Biologics Investigational Site
Bochnia, Poland
Synthetic Biologics Investigational Site
Bydgoszcz, Poland
Synthetic Biologics Investigational Site
Chodzież, Poland
Synthetic Biologics Investigational Site
Lodz, Poland
Synthetic Biologics Investigational Site
Oława, Poland
Synthetic Biologics Investigational Site
Pomorskie, Poland
Synthetic Biologics Investigational Site
Siedlce, Poland
Synthetic Biologics Investigational Site
Tarnów, Poland
SyntheticBiologics Investigational Site
Tychy, Poland
Synthetic Biologics Investigational Site
Warszawice, Poland
Synthetic Biologics Investigational Site
Arad, Romania
Synthetic Biologics Investigational Site
Brasov, Romania
Synthetic Biologics Investigational SIte
Bucharest, Romania
Synthetic Biologics Investigational Site
Cluj-Napoca, Romania
Synthetic Biologics Investigational Site
Oradea, Romania
Synthetic Biologics Investigational Site
Otopeni, Romania
Synthetic Biologics Investigational Site
Timișoara, Romania
Synthetic Biologics Investigational Site
Belgrade, Serbia
Synthetic Biologics Investigational Site
Čačak, Serbia
Synthetic Biologics Investigational Site
Gornji Matejevac, Serbia
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.